Literature DB >> 22263088

Inoperable stage III non-small cell lung cancer: Current treatment and role of vinorelbine.

Mariano Provencio1, Dolores Isla, Antonio Sánchez, Blanca Cantos.   

Abstract

Most lung cancer patients are diagnosed with a non-resectable disease; and around 40% in advanced stages. Stage III non-small cell lung cancer (NSCLC) is a heterogeneous disease with great variations in its clinical extent which presents a major therapeutic challenge. Although chemo-radiotherapy treatment has become the most widely used, there is currently no consensus on the best standard treatment and the experience of the therapy team plays an important role in the decision taking. We review the treatment of inoperable stage III NSCLC and the role of concomitant vinorelbine in this clinical scenario.

Entities:  

Keywords:  chemo-radiotherapy; chemotherapy; non-small cell lung cancer; stage III; vinorelbine

Year:  2011        PMID： 22263088      PMCID： PMC3256525          DOI： 10.3978/j.issn.2072-1439.2011.01.02

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


  49 in total

1.  Oral vinorelbine pharmacokinetics and absolute bioavailability study in patients with solid tumors.

Authors:  M Marty; P Fumoleau; A Adenis; Y Rousseau; Y Merrouche; G Robinet; I Senac; C Puozzo
Journal:  Ann Oncol       Date:  2001-11       Impact factor: 32.976

2.  Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: a randomized phase II locally advanced multi-modality protocol.

Authors:  Chandra P Belani; Hak Choy; Phil Bonomi; Charles Scott; Patrick Travis; John Haluschak; Walter J Curran
Journal:  J Clin Oncol       Date:  2005-08-08       Impact factor: 44.544

3.  Radiotherapy alone versus combined chemotherapy and radiotherapy in unresectable non-small cell lung carcinoma.

Authors:  T Le Chevalier; R Arriagada; E Quoix; P Ruffie; M Martin; J Y Douillard; M Tarayre; M J Lacombe-Terrier; A Laplanche
Journal:  Lung Cancer       Date:  1994-03       Impact factor: 5.705

Review 4.  Developments in cytotoxic chemotherapy: advances in treatment utilising vinorelbine.

Authors:  M S Aapro; P Harper; S A Johnson; J B Vermorken
Journal:  Crit Rev Oncol Hematol       Date:  2001-12       Impact factor: 6.312

5.  Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III Non-small-cell lung cancer: Cancer and Leukemia Group B.

Authors:  Everett E Vokes; James E Herndon; Michael J Kelley; M Giulia Cicchetti; Nithya Ramnath; Harvey Neill; James N Atkins; Dorothy M Watson; Wallace Akerley; Mark R Green
Journal:  J Clin Oncol       Date:  2007-04-02       Impact factor: 44.544

6.  Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.

Authors:  K Furuse; M Fukuoka; M Kawahara; H Nishikawa; Y Takada; S Kudoh; N Katagami; Y Ariyoshi
Journal:  J Clin Oncol       Date:  1999-09       Impact factor: 44.544

Review 7.  Concurrent chemoradiotherapy in non-small cell lung cancer.

Authors:  Noelle O'Rourke; Marta Roqué I Figuls; Nuria Farré Bernadó; Fergus Macbeth
Journal:  Cochrane Database Syst Rev       Date:  2010-06-16

8.  Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group.

Authors:  Jean-Pierre Pignon; Hélène Tribodet; Giorgio V Scagliotti; Jean-Yves Douillard; Frances A Shepherd; Richard J Stephens; Ariane Dunant; Valter Torri; Rafael Rosell; Lesley Seymour; Stephen G Spiro; Estelle Rolland; Roldano Fossati; Delphine Aubert; Keyue Ding; David Waller; Thierry Le Chevalier
Journal:  J Clin Oncol       Date:  2008-05-27       Impact factor: 44.544

9.  Non-small-cell lung cancer in elderly patients: influence of age on vinorelbine oral pharmacokinetics.

Authors:  Christian Puozzo; Cesare Gridelli
Journal:  Clin Lung Cancer       Date:  2004-01       Impact factor: 4.785

10.  Inoperable non-small cell lung cancer: radiation with or without chemotherapy.

Authors:  K Mattson; L R Holsti; P Holsti; M Jakobsson; M Kajanti; K Liippo; M Mäntylä; S Niitamo-Korhonen; V Nikkanen; E Nordman
Journal:  Eur J Cancer Clin Oncol       Date:  1988-03
View more
  21 in total

1.  Early Detection of Recurrence in Patients With Locally Advanced Non-Small-Cell Lung Cancer via Circulating Tumor Cell Analysis.

Authors:  Chimbu Chinniah; Louise Aguarin; Phillip Cheng; Cristina Decesaris; Alicia Cutillo; Abigail T Berman; Melissa Frick; Abigail Doucette; Keith A Cengel; William Levin; Stephen Hahn; Jay F Dorsey; Charles B Simone; Gary D Kao
Journal:  Clin Lung Cancer       Date:  2019-05-04       Impact factor: 4.785

2.  Modern radiotherapy using image guidance for unresectable non-small cell lung cancer can improve outcomes in patients treated with chemoradiation therapy.

Authors:  Matthew P Deek; Sinae Kim; Ning Yue; Rekha Baby; Inaya Ahmed; Wei Zou; John Langenfeld; Joseph Aisner; Salma K Jabbour
Journal:  J Thorac Dis       Date:  2016-09       Impact factor: 2.895

3.  Lung cancer prognosis before and after recurrence in a population-based setting.

Authors:  Dario Consonni; Mariaelena Pierobon; Mitchell H Gail; Maurizia Rubagotti; Melissa Rotunno; Alisa Goldstein; Lynn Goldin; Jay Lubin; Sholom Wacholder; Neil E Caporaso; Pier Alberto Bertazzi; Margaret A Tucker; Angela C Pesatori; Maria Teresa Landi
Journal:  J Natl Cancer Inst       Date:  2015-03-23       Impact factor: 13.506

4.  Antitumor activity of nimotuzumab in combination with cisplatin in lung cancer cell line A549 in vitro.

Authors:  Yanhong Yang; Wenwen Zhou; Jiandong Wu; Lixin Yao; Lei Xue; Qianyi Zhang; Zhenzhen Wang; Xiaoyu Wang; Shu Dong; Jiangman Zhao; Duanduan Yin
Journal:  Oncol Lett       Date:  2018-02-01       Impact factor: 2.967

5.  Six minute walk distance is a predictor of survival in patients with chronic obstructive pulmonary disease undergoing pulmonary rehabilitation.

Authors:  Esther Dajczman; Rima Wardini; Goulnar Kasymjanova; David Préfontaine; Marc Alexander Baltzan; Norman Wolkove
Journal:  Can Respir J       Date:  2015 Jul-Aug       Impact factor: 2.409

6.  Thoracic Vertebral Body Irradiation Contributes to Acute Hematologic Toxicity During Chemoradiation Therapy for Non-Small Cell Lung Cancer.

Authors:  Matthew P Deek; Brian Benenati; Sinae Kim; Ting Chen; Inaya Ahmed; Wei Zou; Joseph Aisner; Salma K Jabbour
Journal:  Int J Radiat Oncol Biol Phys       Date:  2015-09-25       Impact factor: 7.038

7.  TGF-β/Smad signaling through DOCK4 facilitates lung adenocarcinoma metastasis.

Authors:  Jia-Ray Yu; Yilin Tai; Ying Jin; Molly C Hammell; J Erby Wilkinson; Jae-Seok Roe; Christopher R Vakoc; Linda Van Aelst
Journal:  Genes Dev       Date:  2015-02-01       Impact factor: 11.361

8.  Exosomal proteins as potential diagnostic markers in advanced non-small cell lung carcinoma.

Authors:  Kristine R Jakobsen; Birgitte S Paulsen; Rikke Bæk; Kim Varming; Boe S Sorensen; Malene M Jørgensen
Journal:  J Extracell Vesicles       Date:  2015-03-02

9.  Concurrent chemoradiotherapy with vinorelbine plus split-dose cisplatin may be an option in inoperable stage III non-small cell lung cancer: a single-center experience.

Authors:  Hüseyin Mertsoylu; Fatih Köse; Ahmet Taner Sümbül; Ali Murat Sedef; Özlem Doğan; Ali Ayberk Besen; Cem Parlak; Alper Fındıkçıoğlu; Sadık Muallaoğlu; Ahmet Sezer; Hakan Sakallı; Özgür Özyılkan
Journal:  Med Sci Monit       Date:  2015-03-03

10.  Feasibility, tolerability, and efficacy of the concurrent addition of erlotinib to thoracic radiotherapy in locally advanced unresectable non-small-cell lung cancer: a Phase II trial.

Authors:  Enrique Martínez; Maite Martínez; Mikel Rico; Berta Hernández; Francesc Casas; Nuria Viñolas; Ana Pérez-Casas; Manuel Dómine; Julián Mínguez
Journal:  Onco Targets Ther       Date:  2016-03-01       Impact factor: 4.147
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.